Targeted treatment for conjunctival melanoma harboring a BRAF mutation could be considered since the genetic profile is similar to that of cutaneous melanoma in which BRAF/MEK inhibitors are used. This evidence concerns the gene BRAF and malignant conjunctival melanoma.